Rayner Pharmaceuticals limited have informed the MHRA that the batches listed in this notification do not include the concentration of phosphates in the product information.
Similar Posts
MHRA confirms taking paracetamol during pregnancy remains safe and there is no evidence it causes autism in children
Paracetamol should be taken as directed in the patient information leaflet
Class 3 Medicines Recall: Glenmark Pharmaceuticals Europe Limited, Fingolimod Glenmark 0.5 mg Hard Capsules, EL(26)A/02
Glenmark Pharmaceuticals Europe Limited is recalling one batch after stability testing showed out-of-specification results. The batch is being recalled as a precautionary measure following test results that showed a delay in capsule dissolution.
MHRA appoints first Chief Medical and Scientific Officer
Professor Jacob George has been appointed as the first Chief Medical and Scientific Officer for the Medicines and Healthcare products Regulatory Agency (MHRA).
Updated guidance on the management of the recalled Endologix Nellix EndoVascular Aneurysm Sealing (EVAS) System (DSI/2025/004)
The MHRA provides an update to previous guidance on the management of patients treated with the recalled Endologix Nellix EVAS System to reflect revised recommendations. All implanted patients in the UK with this device should be identified and appropriate action taken.
New Commission to help accelerate NHS use of AI
New National Commission unites clinical leaders, patient advocates and leading tech firms to make the NHS the most AI-enabled healthcare system in world
Borderline products: how to tell if your product is a medicine
How the MHRA makes decisions on what is a medicinal product (borderline products).